Company: TAK
Filing Date: 2025-07-01
Form Type: 6-K
Source: 0001395064-25-000107
Chunk: 2

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-07-01
Form: 6-K
Chunk 2
---
,477,018 |     | Approval (97.33%)        |     |                       |
| Proposal No.3       |     |                       7,737,292 |     |                      3,623,372 |     |                            19,984 |     |                           11,477,246 |     | Approval (67.41%)        |     | (Note) 1              |

(Note)

1. Approval requires a majority of the voting rights of shareholders in attendance and able to exercise voting rights.

2. Approval requires the attendance of shareholders possessing at least one third of the voting rights of shareholders who are able to exercise voting rights and a majority of the voting rights of shareholders in attendance.

[4] Reason for not adding some of the voting rights of shareholders who attended the Annual General Meeting of Shareholders to the number of voting rights for approval of, against or abstaining from each of the items to be resolved

The requirements for approval of the resolutions were met by the advance voting by the day prior to the date of this Annual General Meeting of Shareholders and the tallying of votes received from some of the shareholders who attended on the day of the meeting for which the approval or otherwise of the resolutions could be confirmed, and the resolutions were thus passed legally in accordance with the Companies Act. Therefore, the remaining votes of shareholders who attended on the day of this Annual General Meeting of Shareholders were not added to the number of voting rights for approval of, against or abstaining from each of the items to be resolved.

End of Document